180 related articles for article (PubMed ID: 34864334)
1. The highlights of the 15th international conference of the international mesothelioma interest group - Do molecular concepts challenge the traditional approach to pathological mesothelioma diagnosis?
Klebe S; Galateau Salle F; Bruno R; Brcic L; I Chen-Yost H; Jaurand MC
Lung Cancer; 2022 Jan; 163():1-6. PubMed ID: 34864334
[TBL] [Abstract][Full Text] [Related]
2. Update of pathological diagnosis of pleural mesothelioma using genomic-based morphological techniques, for both histological and cytological investigations.
Nabeshima K; Hamasaki M; Kinoshita Y; Matsumoto S; Sa-Ngiamwibool P
Pathol Int; 2022 Aug; 72(8):389-401. PubMed ID: 35596704
[TBL] [Abstract][Full Text] [Related]
3. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
Aydogdu G; Özekinci S
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
5. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
6. Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology.
Louw A; van Vliet C; Peverall J; Colkers S; Acott N; Creaney J; Lee YCG; Chai SM
Cancer Cytopathol; 2022 May; 130(5):352-362. PubMed ID: 35143119
[TBL] [Abstract][Full Text] [Related]
7. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
[TBL] [Abstract][Full Text] [Related]
8. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
[TBL] [Abstract][Full Text] [Related]
9. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
[TBL] [Abstract][Full Text] [Related]
10. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
Berg KB; Churg AM; Cheung S; Dacic S
Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
[TBL] [Abstract][Full Text] [Related]
12. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
13. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.
Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kasai T; Hiroshima K; Kushitani K; Takeshima Y; Kawahara K; Iwasaki A; Nabeshima K
Ann Diagn Pathol; 2022 Oct; 60():152004. PubMed ID: 35797798
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study.
Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Kasai T; Kushitani K; Takeshima Y; Hiroshima K; Iwasaki A; Nabeshima K
Lung Cancer; 2023 Jan; 175():27-35. PubMed ID: 36442384
[TBL] [Abstract][Full Text] [Related]
16. A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas.
Brcic L; Le Stang N; Gallob F; Pissaloux D; Sequeiros R; Paindavoine S; Pairon JC; Karanian M; Dacic S; Girard N; Churg A; Tirode F; Galateau-Salle F
Arch Pathol Lab Med; 2023 Mar; 147(3):313-322. PubMed ID: 35738002
[TBL] [Abstract][Full Text] [Related]
17. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
[TBL] [Abstract][Full Text] [Related]
18. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
[TBL] [Abstract][Full Text] [Related]
19. Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Iwasaki A; Nabeshima K
Mod Pathol; 2020 Feb; 33(2):235-244. PubMed ID: 31231129
[TBL] [Abstract][Full Text] [Related]
20. Sarcomatoid mesothelioma diagnosed in a patient with mesothelioma in situ: a case report on morphologic differences after 9-month interval with details analysis of cytology in early-stage mesothelioma.
Yoshida M; Jimbo N; Tsukamoto R; Itoh T; Kawahara K; Mitsui S; Tanaka Y; Maniwa Y
Diagn Pathol; 2023 Nov; 18(1):126. PubMed ID: 38017544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
